122 related articles for article (PubMed ID: 35964660)
41. AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma.
Geng N; Jin Y; Li Y; Zhu S; Bai H
Int J Med Sci; 2020; 17(9):1246-1256. PubMed ID: 32547320
[TBL] [Abstract][Full Text] [Related]
42. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
[TBL] [Abstract][Full Text] [Related]
43. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
Kashima K; Sato N; Sato K; Shimizu H; Mori M
Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
[TBL] [Abstract][Full Text] [Related]
44. Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Reddy KA; Kumar PU; Srinivasulu M; Triveni B; Sharada K; Ismail A; Reddy GB
Breast; 2017 Feb; 31():137-143. PubMed ID: 27855345
[TBL] [Abstract][Full Text] [Related]
45. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules.
Okayama N; Omi H; Okouchi M; Imaeda K; Kato T; Akao M; Imai S; Shimizu M; Fukutomi T; Itoh M
J Diabetes Complications; 2002; 16(5):321-6. PubMed ID: 12200074
[TBL] [Abstract][Full Text] [Related]
47. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
[TBL] [Abstract][Full Text] [Related]
48. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H
Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234
[TBL] [Abstract][Full Text] [Related]
49. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Isogai S; Inokuchi T; Ohe K
Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
[TBL] [Abstract][Full Text] [Related]
50. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
Schemmel KE; Padiyara RS; D'Souza JJ
J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
[TBL] [Abstract][Full Text] [Related]
51. Epalrestat prevents the decrease in gastric mucosal blood flow and protects the gastric mucosa in streptozotocin diabetic rats.
Suzuki H; Shimosegawa T; Ohara S; Toyota T
J Gastroenterol; 1999 Apr; 34(2):172-7. PubMed ID: 10213114
[TBL] [Abstract][Full Text] [Related]
52. [Protective Effect of Epalrestat against Oxidative Stress-induced Cytotoxicity].
Tatsunami R; Murao Y; Sato K
Yakugaku Zasshi; 2020; 140(11):1381-1388. PubMed ID: 33132274
[TBL] [Abstract][Full Text] [Related]
53. Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
Yasuda H; Hirai A; Joko M; Terada M; Kawabata T; Maeda K; Haneda M; Kashiwagi A; Maeda T; Kikkawa R
Diabetes Care; 2000 May; 23(5):705. PubMed ID: 10834436
[No Abstract] [Full Text] [Related]
54. LC-MS/MS method for the quantification of aldose reductase inhibitor-epalrestat and application to pharmacokinetic study.
Nirogi R; Kandikere V; Ajjala DR; Bhyrapuneni G; Muddana NR
J Pharm Biomed Anal; 2013 Feb; 74():227-34. PubMed ID: 23245255
[TBL] [Abstract][Full Text] [Related]
55. Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS.
Wang X; Yu F; Zheng WQ
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):294-303. PubMed ID: 31389594
[TBL] [Abstract][Full Text] [Related]
56. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
Kinekawa F; Kubo F; Matsuda K; Fujita Y; Kobayashi M; Funakoshi F; Uchida N; Watanabe S; Tomita T; Uchida Y; Kuriyama S
Hepatogastroenterology; 2005; 52(62):471-4. PubMed ID: 15816460
[TBL] [Abstract][Full Text] [Related]
57. Ischemic postconditioning during reperfusion attenuates oxidative stress and intestinal mucosal apoptosis induced by intestinal ischemia/reperfusion via aldose reductase.
Wen SH; Ling YH; Li Y; Li C; Liu JX; Li YS; Yao X; Xia ZQ; Liu KX
Surgery; 2013 Apr; 153(4):555-64. PubMed ID: 23218881
[TBL] [Abstract][Full Text] [Related]
58. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
59. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives.
Celestina SK; Sundaram K; Ravi S
Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051
[TBL] [Abstract][Full Text] [Related]
60. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
